Sacituzumab Govitecan Plus Pembrolizumab Proves Active in Advanced Urothelial Carcinoma


A combination of sacituzumab govitecan and pembrolizumab showed a “high response rate” in patients with advanced urothelial carcinoma previously treated with platinum-based chemotherapy. In the TROPHY-U-01 trial cohort, 41 patients were treated with the combination, and a 41% objective response rate was observed. The median duration of response was 11.1 months, median progression-free survival was 5.3 months, and median overall survival was 12.7 months. Treatment-related adverse events were observed in all patients, with grade 3 or higher events occurring in 61% of patients. The researchers concluded that the combination supports further evaluation in advanced urothelial carcinoma. This research was supported by Gilead Sciences, Inc.

Source link

error: Content is protected !!